<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>There are growing data and a continuing controversy over the effect of <z:chebi fb="9" ids="27470">folic acid</z:chebi> supplementation on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk </plain></SENT>
<SENT sid="1" pm="."><plain>We conducted a meta-analysis based on up-to-date published relevant randomized trials to further examine this issue </plain></SENT>
<SENT sid="2" pm="."><plain>Relative risk (RR) was used to measure the effect of <z:chebi fb="9" ids="27470">folic acid</z:chebi> supplementation on risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> using a random-effects model </plain></SENT>
<SENT sid="3" pm="."><plain>Overall, <z:chebi fb="9" ids="27470">folic acid</z:chebi> supplementation had no significant effect on total <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence (13 trials, n = 49,406, RR = 1.05; 95% CI: 0.99-1.11, p = 0.13), <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (seven trials, n = 33,824, 1.01; 0.82-1.23, p = 0.95), <z:e sem="disease" ids="C0810238" disease_type="Neoplastic Process" abbrv="">other gastrointestinal cancer</z:e> (two trials, n = 20,228, 1.00; 0.75-1.33, p = 0.99), <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> (five trials, n = 27,065, 1.17; 0.84-1.62, p = 0.35), other <z:e sem="disease" ids="C0751569" disease_type="Neoplastic Process" abbrv="">genitourinary cancer</z:e> (two trials, n = 20,228, 0.97; 0.75-1.27, p = 0.84), <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> (five trials, n = 31,864, 1.00; 0.84-1.21, p = 0.97), <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (four trials, n = 19,800, 0.82; 0.63-1.07, p = 0.15), <z:e sem="disease" ids="C0848852,C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancy</z:e> (three trials, n = 25,670, 0.87; 0.64-1.17, p = 0.35) and total <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality (six trials, n = 31,930, 1.02; 0.90-1.15, p = 0.81) </plain></SENT>
<SENT sid="4" pm="."><plain>However, a significantly reduced risk was observed for <z:hpo ids='HP_0002861'>melanoma</z:hpo> (three trials, n = 19,128, 0.47; 0.23-0.94, p = 0.03) </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, higher total <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence risk was observed among those trials with a higher percent use of <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering drugs (&gt;60%, 1.10; 1.00-1.20, p = 0.04), or with lower percent baseline <z:hpo ids='HP_0000822'>hypertension</z:hpo> (≤70%, 1.08; 1.00-1.16, p = 0.057).Consistently, meta-regression analyses suggested that the similar trend between percent use of <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering drugs (p = 0.084) or percent baseline <z:hpo ids='HP_0000822'>hypertension</z:hpo> (p = 0.056) and log-RR for total <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence associated with <z:chebi fb="9" ids="27470">folic acid</z:chebi> supplementation </plain></SENT>
<SENT sid="6" pm="."><plain>Our findings indicate that <z:chebi fb="9" ids="27470">folic acid</z:chebi> supplementation has no significant effect on total <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, <z:hpo ids='HP_0012125'>prostate cancer</z:hpo>, <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e>, <z:hpo ids='HP_0003002'>breast cancer</z:hpo> or <z:e sem="disease" ids="C0848852,C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancy</z:e>, but reduces the risk of <z:hpo ids='HP_0002861'>melanoma</z:hpo> </plain></SENT>
</text></document>